Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Fineline Cube Sep 10, 2026
Company Drug

NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China

Fineline Cube Sep 10, 2026
Company Deals

Moonwalk Biosciences Closes Oversubscribed USD 70 Million Series B – Eli Lilly Joins Alpha Wave and YK Bioventures to Back First‑in‑Class Adipose‑Targeted siRNA Candidate MW101

Fineline Cube Sep 10, 2026
Company Deals

Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine

Fineline Cube Nov 19, 2025

Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...

Policy / Regulatory

NMPA Releases 98th RLD Catalog for Chemical Generics, Adding 48 New Specifications

Fineline Cube Nov 19, 2025

China’s National Medical Products Administration (NMPA) released the ninety-eighth batch of the Reference Listed Drugs...

Company Drug

Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma

Fineline Cube Nov 19, 2025

Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has granted...

Company Drug

Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial

Fineline Cube Nov 19, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced its investigational oral SERD giredestrant met the primary endpoint...

Company Drug

Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑6209 capsules, a novel...

Company Deals

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic

Fineline Cube Nov 18, 2025

Gate Bioscience announced the close of its oversubscribed USD 65 million Series B financing led by...

Company Drug

Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS‑4642, a home‑developed KRAS...

Company

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First

Fineline Cube Nov 18, 2025

Takeda China, a subsidiary of Takeda Pharmaceutical Co. (TYO: 4502, NYSE: TAK), announced the official...

Company Drug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Fineline Cube Nov 18, 2025

BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) announced its HER2‑targeted bispecific antibody zanidatamab (Ziihera)...

Company Drug

Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First

Fineline Cube Nov 18, 2025

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced its antibody-drug conjugate iza-bren (izalontamab brengitecan, BL‑B01D1)...

Company Deals

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy

Fineline Cube Nov 18, 2025

Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage...

Company Drug

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients

Fineline Cube Nov 18, 2025

Bristol‑Myers Squibb (BMS, NYSE: BMY) and Johnson & Johnson (J&J, NYSE: JNJ) announced the premature...

Company Drug

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients

Fineline Cube Nov 18, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that its μ‑opioid receptor (MOR)‑biased...

Company Deals

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915

Fineline Cube Nov 18, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced a definitive agreement to acquire Halda Therapeutics in an all‑cash...

Company Drug

Lundbeck’s Vyepti Secures Chinese NDA, Expands Asian Footprint

Fineline Cube Nov 17, 2025

Lundbeck A/S (OTCMKTS: HLUBF) announced that the Center for Drug Evaluation (CDE) of China’s National...

Company Deals

Suzhou Zelgen Biopharma to Deregister U.S. Subsidiary Gensun to Sharpen R&D Focus

Fineline Cube Nov 17, 2025

Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced plans to de‑register and cancel its U.S. subsidiary,...

Company Drug

Akeso Secures NMPA Approval for AK152 – First Bispecific Antibody Targeting Alzheimer’s in China

Fineline Cube Nov 17, 2025

Akeso Inc. (HKG: 9926) announced that its self‑developed bispecific antibody AK152 has received regulatory approval...

Company Deals

MSD Acquires Cidara Therapeutics in $9.2‑Billion Deal to Expand Antiviral Portfolio

Fineline Cube Nov 17, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics, Inc....

Company Drug

Abbisko Therapeutics Reports Durable Response in Phase 3 MANEUVER Study for Pimicotinib (ABSK021) in TGCT

Fineline Cube Nov 17, 2025

Abbisko Therapeutics Co., Ltd. (HKG: 2256) released long‑term efficacy, safety and patient‑reported outcome data from its...

Company Drug

Zhejiang Jianfeng Group Secures NMPA Approval for JFAN‑1001/ Vinorelbine Combination in Advanced NSCLC

Fineline Cube Nov 17, 2025

Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668) announced that its subsidiary Jianfeng Yien Biotechnology has obtained...

Posts pagination

1 … 130 131 132 … 718

Recent updates

  • NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China
  • Moonwalk Biosciences Closes Oversubscribed USD 70 Million Series B – Eli Lilly Joins Alpha Wave and YK Bioventures to Back First‑in‑Class Adipose‑Targeted siRNA Candidate MW101
  • Full-Life Technologies Secures FDA IND Clearance for [²²⁵Ac]Ac‑FL‑261 – Potential First‑in‑Class c‑MET Alpha Radionuclide Conjugate Enters Phase I in Non‑Squamous NSCLC
  • CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy
  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Accepts Yantai Dongcheng’s Marketing Application for Bemiparin Sodium Injection – Potential First Generic of Ultra‑Low Molecular Weight Heparin in China

Company Deals

Moonwalk Biosciences Closes Oversubscribed USD 70 Million Series B – Eli Lilly Joins Alpha Wave and YK Bioventures to Back First‑in‑Class Adipose‑Targeted siRNA Candidate MW101

Company Drug

Full-Life Technologies Secures FDA IND Clearance for [²²⁵Ac]Ac‑FL‑261 – Potential First‑in‑Class c‑MET Alpha Radionuclide Conjugate Enters Phase I in Non‑Squamous NSCLC

Company Deals PIC

CellStore Signs Strategic Partnership Memorandum With Shanghai Cell Therapy Group – Deepening Cooperation in Cell Cryopreservation, Product Application Validation, and Industrial Synergy Across Cell and Gene Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.